Zobrazeno 1 - 10
of 26
pro vyhledávání: '"probuphine"'
Autor:
Itzoe M, Guarnieri M
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 11, Pp 1429-1437 (2017)
MariaLisa Itzoe, Michael Guarnieri Department of Neurological Surgery, Johns Hopkins School of Medicine, Baltimore, MD, USA Abstract: Opioid addiction to prescription and illicit drugs is a serious and growing problem. In the US alone, >2.4 million p
Externí odkaz:
https://doaj.org/article/b5faed271ff344f9a6a3a68070b20196
Autor:
Michael Guarnieri, MariaLisa Itzoe
Publikováno v:
Drug Design, Development and Therapy
Opioid addiction to prescription and illicit drugs is a serious and growing problem. In the US alone, >2.4 million people suffer from opioid use disorder. Government and pharmaceutical agencies have begun to address this crisis with recently released
Autor:
William J. Lorman
Publikováno v:
Journal of addictions nursing. 30(2)
Publikováno v:
Therapeutic Advances in Psychopharmacology. 7:119-134
Opioid dependence leads to physical dependence and addiction which finally results in profound medical, psychological and social dysfunction. One of the useful medications for opioid dependence is buprenorphine, the partial opioid agonist, which is u
Autor:
Raymond Bobb, Michael Frost
Publikováno v:
Journal of addiction medicine. 13(1)
A long-acting buprenorphine subdermal implant, Probuphine, was approved by the Food and Drug Administration (FDA) in May 2016, for the maintenance treatment of patients with opioid-use disorder. Long-acting implants offer the potential benefits of im
Autor:
Alison Knopf
Publikováno v:
Alcoholism & Drug Abuse Weekly. 28:1-3
Autor:
Alison Knopf
Publikováno v:
Alcoholism & Drug Abuse Weekly. 28:1-3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Substance Abuse and Rehabilitation
Substance abuse and rehabilitation, vol 2, iss 1
Substance abuse and rehabilitation, vol 2, iss 1
Pharmacotherapies for opioid addiction under active development in the US include lofexidine (primarily for managing withdrawal symptoms) and Probuphine®, a distinctive mode of delivering buprenorphine for six months, thus relieving patients, clinic
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.